• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amgen tops Q4 earnings, touts Repatha cardiovascular outcomes

February 3, 2017 By Sarah Faulkner

Amgen tops Q4 earnings, touts Repatha cardiovascular outcomesShares in Amgen (NSDQ:AMGN) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results and touted data from a trial for its cholesterol drug, Repatha.

The Thousand Oaks, Calif.-based company posted profits of $1.94 billion, or $2.59 per share, on sales of $5.97 billion for the 3 months ended Dec. 31, for bottom-line growth of 8% on sales growth of 8% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $2.89, ahead of consensus on The Street, where analysts were looking for sales of $5.74 billion.

“We finished the year with strong operating performance,” chairman & CEO Robert Bradway said in prepared remarks. “We anticipate several new product development opportunities and launches in 2017, and are excited about the Repatha cardiovascular outcomes data we released today. We have established a firm foundation for longer-term growth.”

Amgen said it expects to post adjusted EPS of $11.80 to $12.60 on sales of $22.3 billion to $23.1 billion for 2017.

AMGN shares were trading at $166.12 apiece today in afternoon trading, up 4.1%.

The company touted data yesterday from a trial evaluating its cholesterol injection Repatha. The study found that the drug reduced the risk of heart attacks, strokes and cardiac death in a patient population with heart disease. The trial results are a victory for Amgen, since pharmacy benefit managers and health insurers have been rejecting 75% of Repatha prescriptions while awaiting more evidence of the drug’s benefits, Reuters reported.

In December, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion for Amgen’s Repatha single monthly injection device. The device is already cleared in Europe for dosing every 2 weeks.

The hands-free device, with prefilled cartridges, delivers 420 milligrams of Repatha (evolocumab) in a single injection. Repatha, a human monoclonal antibody, inhibits a protein which is responsible for blocking the body’s system that naturally eliminates low-density lipoprotein cholesterol.

If the device is approved by the European Commission, it would be the 1st inhibitor of its kind in Europe with a single monthly injection option. The FDA approved the single monthly injection device in July this year.

Filed Under: Cardiovascular, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Amgen

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS